Clinical, Radiographical, Histological Evaluation and Blood Flow Analysis of Alveolar Ridge Preservation
Launched by SEMMELWEIS UNIVERSITY · Dec 30, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at ways to help preserve the bone in your jaw after a tooth is removed. When a tooth is extracted, it can lead to a loss of bone, which can affect future dental procedures, like getting implants. The researchers want to see if two specific methods—using a technique called extraction side development (XSD) and a type of bone graft made from your own tooth (autogenous tooth bone graft or ATB)—are effective in reducing this bone loss.
To participate in the trial, you need to be at least 18 years old and have good oral hygiene. You should also be undergoing treatment for gum disease, but it must not be severely inflamed. However, if you have certain health conditions, like active infections, serious heart problems, or if you are pregnant or breastfeeding, you might not be eligible. If you join the study, you will help researchers understand these techniques better, and you may benefit from improved bone preservation after your tooth extraction.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Women and men Patients over 18 years Co-operative patients with good individual oral hygiene (FMBS: 25%\>) Patients with periodontal disease in treatment or under treatment with minimal active inflammation (FMPS: 25%\>)
- Local criteria:
- • Teeth with a hopeless prognosis with advanced periodontal or endo-periodontal defects, which are restored with implant prosthesis EDS 3-4 extraction defects after tooth extraction
- Exclusion Criteria:
- • Infectious diseases (HBV, HCV, HIV, CoV-2019...) Current chemotherapy or radiotherapy Previous radiation therapy to the head and neck region (in the last 2 years) Untreated insulin dependent diabetes mellitus Clinically significant osteoporosis or other systemic disease affecting bone metabolism Clinically significant circulatory disorder e.g.: decompensated cardiac failure Haemodynamically significant valvular heart failure or myocardial infarction within the last 3 months Clinically significant coagulopathy Current or previous systemic corticosteroid therapy (in the last 2 months) Current or previous systemic bisphosphonate therapy (beyond 30 days) Pregnant or breastfeeding women Smoking (max 5 cigarettes per day) Drug addiction, alcoholism
About Semmelweis University
Semmelweis University, located in Budapest, Hungary, is a prestigious institution renowned for its commitment to advancing medical education, research, and healthcare innovation. As a prominent clinical trial sponsor, the university leverages its extensive expertise in various medical fields to conduct rigorous clinical studies aimed at improving patient outcomes and enhancing therapeutic strategies. With a focus on ethical standards and scientific excellence, Semmelweis University collaborates with a network of healthcare professionals and researchers to translate groundbreaking discoveries into practical applications, ultimately contributing to the global advancement of medical science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Budapest, , Hungary
Patients applied
Trial Officials
Balint Molnar
Principal Investigator
Department of Periodontology,Semmelweis University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials